Sarepta Therapeutics (SRPT) Share-based Compensation (2010 - 2026)

Sarepta Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $33.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 18.72% year-over-year to $33.7 million; the TTM figure through Mar 2026 stood at $132.7 million (down 35.55% YoY), while the FY2025 annual figure was $139.1 million, down 32.2% from the prior year.
• Share-based Compensation was $33.7 million for Q1 2026 at Sarepta Therapeutics, down from $45.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $102.9 million in Q2 2022 to a low of $16.4 million in Q3 2025.
• Historically, Share-based Compensation has averaged $47.0 million across 5 years, with a median of $45.7 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 254.8% in 2022, then tumbled 62.31% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $50.5 million in 2022, then decreased by 9.3% to $45.8 million in 2023, then surged by 53.96% to $70.5 million in 2024, then sank by 35.24% to $45.7 million in 2025, then dropped by 26.28% to $33.7 million in 2026.
• The last three Share-based Compensation figures came in at $33.7 million (Q1 2026), $45.7 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.